Neofytos D, Kobayashi K, Alonso C D, Cady-Reh J, Lepley D, Harris M, Desai N, Kraus E, Subramanian A, Treadway S, Ostrander D, Thompson C, Marr K
Department of Medicine, School of Medicine, The Johns Hopkins University, Baltimore, Maryland 21205, USA.
Transpl Infect Dis. 2013 Apr;15(2):134-41. doi: 10.1111/tid.12030. Epub 2012 Nov 23.
We sought to describe the epidemiology and risk factors for Clostridium difficile infection (CDI) among kidney transplant recipients (KTR) between 1 January 2008 and 31 December 2010.
A single-institution retrospective study was conducted among all adult KTR with CDI, defined as a positive test for C. difficile by a cell cytotoxic assay for C. difficile toxin A or B or polymerase chain reaction test for toxigenic C. difficile.
Among 603 kidney transplants performed between 1 January 2008 and 31 December 2010, 37 (6.1%) patients developed CDI: 12 (of 128; 9.4%) high-risk (blood group incompatible and/or anti-human leukocyte antigen donor-specific antibodies) vs. 25 (of 475; 5.3%, P = 0.08) standard-risk patients. The overall rate of CDI increased from 3.7% in 2008 to 9.4% in 2010 (P = 0.05). The median time to CDI diagnosis was 9 days, with 27 (73.0%) patients developing CDI within the first 30 days after their transplant, and 14 (51.8%) developing CDI within 7 days. A case-control analysis of 37 CDI cases and 74 matched controls demonstrated the following predictors for CDI among KTR: vancomycin-resistant Enterococcus colonization before transplant (odds ratio [OR]: 3.6, P = 0.03), receipt of an organ from Centers for Disease Control high-risk donor (OR: 5.9, P = 0.006), and administration of high-risk antibiotics within 30 days post transplant (OR: 6.6, P = 0.001).
CDI remains a common early complication in KTR, with rates steadily increasing during the study period. Host and transplant-related factors and exposure to antibiotics appeared to significantly impact the risk for CDI among KTR.
我们试图描述2008年1月1日至2010年12月31日期间肾移植受者(KTR)中艰难梭菌感染(CDI)的流行病学及危险因素。
对所有患有CDI的成年KTR进行了一项单机构回顾性研究,CDI定义为通过艰难梭菌毒素A或B的细胞毒性试验或产毒艰难梭菌的聚合酶链反应检测,艰难梭菌检测呈阳性。
在2008年1月1日至2010年12月31日期间进行的603例肾移植中,37例(6.1%)患者发生了CDI:12例(128例中的12例;9.4%)高危患者(血型不相容和/或抗人类白细胞抗原供体特异性抗体),与25例(475例中的25例;5.3%,P = 0.08)标准风险患者。CDI的总体发生率从2008年的3.7%增至2010年的9.4%(P = 0.05)。CDI诊断的中位时间为9天,27例(73.0%)患者在移植后的前30天内发生CDI,14例(51.8%)在7天内发生CDI。对37例CDI病例和74例匹配对照进行的病例对照分析显示,KTR中CDI的预测因素如下:移植前耐万古霉素肠球菌定植(比值比[OR]:3.6,P = 0.03)、接受来自疾病控制中心高危供体的器官(OR:5.9,P = 0.006)以及移植后30天内使用高危抗生素(OR:6.6,P = 0.001)。
CDI仍然是KTR常见的早期并发症,在研究期间发生率稳步上升。宿主和移植相关因素以及抗生素暴露似乎对KTR中CDI的风险有显著影响。